Zika Virus Therapeutics Market 2024-2028: Size and Asymptomatic nature of the infection; growth driven by the Product, Some of key Companies Positioned Strategically

The zika virus therapeutics market size by Product (Acetaminophen and Other NSAIDs) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 4174.3 million. The market is expected to grow at a CAGR of   4.5% between 2024 and 2028.

• The asymptomatic nature of Zika virus infection, which affects approximately 80% of the infected population, poses a significant challenge to the therapeutics market. This is due to the fact that the absence of discernible symptoms impedes the identification of patients in need of treatment, resulting in a lower incidence rate and decreased market volume and value. Moreover, the underdiagnosis of Zika virus cases creates uncertainty in epidemiological studies, hindering the development of effective transmission dynamics models and control interventions.
• The Zika Virus Therapeutics Market represents a significant business opportunity for pharmaceutical companies, as the demand for effective treatments and vaccines continues to rise. With the World Health Organization declaring Zika a public health emergency in 2016, investments in research and development for Zika virus therapeutics have surged. Market growth is driven by the increasing prevalence of Zika infections, particularly in tropical regions, and the need for effective interventions to mitigate the health and economic impact of the virus. Companies are focusing on developing antiviral drugs, vaccines, and diagnostic tools to address this unmet medical need.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Aurobindo Pharma Ltd.
• Bharat Biotech Ltd.
• BioVaxys Technology Corp.
• Emergent BioSolutions Inc.
• GeoVax Labs Inc.
• Granules India Ltd.
• Inovio Pharmaceuticals Inc.
• Johnson and Johnson Services Inc.
• Merck and Co. Inc.
• Moderna Inc.
• Perrigo Co. Plc
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Valneva SE

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/